AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30602344 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model (CCM) including 10 sessions of the Life Goals self-management program and brief phone contacts by a care manager
Number of subjects: 238
Study 30602344 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 238
Study 28640159 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 30
Study 28640159 — intervention group
Group type: COMPARATOR
Intervention: tDCS-sham
Number of subjects: 30
Study 26398887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus high-potency statin (10mg atorvastatin or 1mg pitavastatin)
Number of subjects: 109
Study 26398887 — intervention group
Group type: COMPARATOR
Intervention: Double dose statin (20mg atorvastatin or 2mg pitavastatin)
Number of subjects: 109
Study 25969561 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 doses of inactivated hepatitis A vaccine (Healive)
Number of subjects: 0
Study 25969561 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of live attenuated hepatitis A vaccine (Biovac)
Number of subjects: 0
Study 24021551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs (copy number variants)
Number of subjects: 223
Study 24021551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs associated with known genomic disorders
Number of subjects: 223
Study 24021551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs prevalence
Number of subjects: 223
Study 24021551 — intervention group
Group type: COMPARATOR
Intervention: Controls (from The Cancer Genome Atlas project)
Number of subjects: 223
Study 21148807 — intervention group
Group type: EXPERIMENTAL
Intervention: supervised exercise
Number of subjects: 202
Study 21148807 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based exercise
Number of subjects: 202
Study 21148807 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 202
Study 21148807 — intervention group
Group type: COMPARATOR
Intervention: placebo pill
Number of subjects: 202
Study 21148807 — intervention group
Group type: EXPERIMENTAL
Intervention: regular exercise during follow-up
Number of subjects: 202
Study 21148807 — intervention group
Group type: COMPARATOR
Intervention: initial treatment group assignment
Number of subjects: 202
Study 21148807 — intervention group
Group type: COMPARATOR
Intervention: antidepressant medication use during follow-up
Number of subjects: 202
Study 18989681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 21
Study 18989681 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral testosterone
Number of subjects: 21
Study 17051456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis standardized extract (10 %)
Number of subjects: 120
Study 17051456 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (2 %)
Number of subjects: 120
Study 12955608 — intervention group
Group type: EXPERIMENTAL
Intervention: Graf ligamentoplasty
Number of subjects: 55
Study 12955608 — intervention group
Group type: COMPARATOR
Intervention: ALIF with Hartshill horseshoe cage
Number of subjects: 55
Study 11111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma (SDP)
Number of subjects: 45
Study 11111235 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 45
Study 9825390 — intervention group
Group type: EXPERIMENTAL
Intervention: Open anterior acromioplasty
Number of subjects: 42
Study 9825390 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy regime
Number of subjects: 42
Study 9825390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to treat analysis for surgery
Number of subjects: 42
Study 9825390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related variables
Number of subjects: 42
Study 7903921 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, 15 mg/wk
Number of subjects: 11
Study 7903921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2689628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 6
Study 2689628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation (Cavitron)
Number of subjects: 6
Study 2689628 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated surfaces)
Number of subjects: 6
Study 1095965 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg S‐adenosylmethionine (SAMe) plus 6000 gamma/day of Vitamin B12
Number of subjects: 20
Study 1095965 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 alone
Number of subjects: 20
Study 30933830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (Thinking Skills for Work program)
Number of subjects: 300
Study 30933830 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 300
Study 29251453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (three different types)
Number of subjects: 25
Study 29251453 — intervention group
Group type: COMPARATOR
Intervention: No-gum control
Number of subjects: 25
Study 25498469 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran extract (WBE) 10 g/d
Number of subjects: 20
Study 25498469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 10 g/d)
Number of subjects: 20
Study 23527300 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX282-B 500 mg once daily
Number of subjects: 436
Study 23527300 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX282-B 250 mg once daily
Number of subjects: 436
Study 23527300 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX282-B 250 mg twice daily
Number of subjects: 436
Study 23527300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 21211500 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone SC QD
Number of subjects: 469
Study 21211500 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone SC QOD
Number of subjects: 469
Study 21211500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 18353329 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa treatment
Number of subjects: 17
Study 18353329 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed volunteers)
Number of subjects: 17
Study 16626272 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year clinical preceptorship
Number of subjects: 0
Study 16626272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12921628 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lactulose (15 - 90 ml/d for 8 weeks)
Number of subjects: 60
Study 12921628 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term lactulose (15 - 90 ml/d for 24 weeks)
Number of subjects: 60
Study 12921628 — intervention group
Group type: COMPARATOR
Intervention: Control (vitamin B complex only for 24 weeks)
Number of subjects: 60
Study 10699232 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-Magnesium Oxide (V-M) combination
Number of subjects: 0
Study 10699232 — intervention group
Group type: COMPARATOR
Intervention: Verapamil-Placebo (V-P) combination
Number of subjects: 0
Study 9088585 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily for 14 days
Number of subjects: 6
Study 9088585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7655642 — intervention group
Group type: EXPERIMENTAL
Intervention: GH in daily injections (0.125 IU.kg‐1. week‐1 for the first 4 weeks and subsequently 0.25 IU.kg‐1. week‐1)
Number of subjects: 68
Study 7655642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 2660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin (500 mg every 12 h)
Number of subjects: 135
Study 2660871 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg every 8 h)
Number of subjects: 135
Study 31781802 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with 0.3% ropivacaine 30 ml at mid-thigh adductor canal
Number of subjects: 150
Study 31781802 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with 0.3% ropivacaine 30 ml at the thigh root-femoral nerve
Number of subjects: 150
Study 31781802 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 30220048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical alignment method
Number of subjects: 60
Study 30220048 — intervention group
Group type: COMPARATOR
Intervention: Kinematic alignment method
Number of subjects: 60
Study 29798565 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation with rhBMP-2 and allogeneic bone grafting
Number of subjects: 48
Study 29798565 — intervention group
Group type: COMPARATOR
Intervention: Short-segment pedicle screw instrumentation with allogeneic bone implanting
Number of subjects: 48
Study 29798565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 25433220 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (8 hours)
Number of subjects: 24
Study 24024839 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-FOLFOX4
Number of subjects: 639
Study 24024839 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 639
Study 20581700 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 2 × 6 g·d)
Number of subjects: 18
Study 20581700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; cornstarch)
Number of subjects: 18
Study 18070163 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 308
Study 16599051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine + 4 ml hypertonic (3%) saline
Number of subjects: 93
Study 16599051 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg epinephrine + 4 ml normal (0.9%) saline
Number of subjects: 93
Study 12555836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain wrap dressing
Number of subjects: 24
Study 12555836 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 24
Study 10674281 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (25 mg/kg body weight p.o.)
Number of subjects: 0
Study 10674281 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine (100 mg p.o. 2 h before GHB)
Number of subjects: 0
Study 9353508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 200 micrograms twice daily for 6 months
Number of subjects: 104
Study 9353508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 1488321 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 65
Study 1488321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 65
Study 1488321 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 65
Study 1488321 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 2996816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radio- and chemotherapy (CCNU) after surgical resection
Number of subjects: 0
Study 31642968 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Vinci (Xi) assisted laparoscopic resection
Number of subjects: 51
Study 31642968 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic resection
Number of subjects: 51
Study 30063658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine infusion
Number of subjects: 100
Study 30063658 — intervention group
Group type: COMPARATOR
Intervention: Control (saline) infusion
Number of subjects: 100
Study 27430558 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60
Study 27430558 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupuncture
Number of subjects: 60
Study 27430558 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction about treatment
Number of subjects: 60
Study 27430558 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 60
Study 24262109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (5mg/kg) in patients undergoing retinal detachment surgery
Number of subjects: 30
Study 24262109 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetazolamide (5mg/kg) in patients undergoing epiretinal membrane peeling
Number of subjects: 30
Study 24262109 — intervention group
Group type: COMPARATOR
Intervention: Comparison between RD surgery and epiretinal membrane peeling groups
Number of subjects: 30
Study 22595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional walking (n = 52)
Number of subjects: 103
Study 22595894 — intervention group
Group type: COMPARATOR
Intervention: Walking with poles (n = 51)
Number of subjects: 103
Study 22595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 20489170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent TBS of the ipsilesional M1
Number of subjects: 10
Study 20489170 — intervention group
Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 10
Study 20489170 — intervention group
Group type: COMPARATOR
Intervention: Continuous TBS of the contralesional M1
Number of subjects: 10
Study 18794430 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antimicrobials (ertapenem)
Number of subjects: 672
Study 18794430 — intervention group
Group type: COMPARATOR
Intervention: Control (cefotetan)
Number of subjects: 672
Study 15921774 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (therapeutic dose)
Number of subjects: 20
Study 15921774 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 20
Study 15921774 — intervention group
Group type: EXPERIMENTAL
Intervention: AD/HD children (off methylphenidate)
Number of subjects: 20
Study 11957163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (induction 15 microg/kg, maintenance 15 microg/kg/hr)
Number of subjects: 195
Study 11957163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (induction 1 microg/kg, maintenance 1 microg/kg/hr)
Number of subjects: 195
Study 11957163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alfentanil and sufentanil (induction with alfentanil 15 microg/kg, maintenance with sufentanil 1 microg/kg/hr)
Number of subjects: 195
Study 11957163 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, S, AS)
Number of subjects: 195
Study 10980844 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (streptokinase, tissue-type plasminogen activator)
Number of subjects: 200000
Study 10980844 — intervention group
Group type: EXPERIMENTAL
Intervention: New thrombolytic agents
Number of subjects: 200000
Study 8775721 — intervention group
Group type: EXPERIMENTAL
Intervention: Kennedy Ligament Augmentation Device (LAD)
Number of subjects: 48
Study 8775721 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone-patellar tendon-bone graft
Number of subjects: 48
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg noscapine tablet
Number of subjects: 20
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg noscapine tablet
Number of subjects: 20
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg noscapine tablet
Number of subjects: 20
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg noscapine solution
Number of subjects: 20
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of noscapine tablets and solution
Number of subjects: 20
Study 2257866 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal half-life of noscapine
Number of subjects: 20
Study 7149946 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral‐physical therapy treatment program including electromyographic feedback
Number of subjects: 37
Study 7149946 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise physical therapy program
Number of subjects: 37
Study 31269001 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing position corresponding to the second pull of the clean
Number of subjects: 17
Study 31269001 — intervention group
Group type: COMPARATOR
Intervention: Bent over torso angle
Number of subjects: 17
Study 28498562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 782
Study 28498562 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 782
Study 28498562 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Expandable (BE) valves
Number of subjects: 782
Study 28498562 — intervention group
Group type: COMPARATOR
Intervention: Non-Balloon Expandable (non-BE) valves
Number of subjects: 782
Study 25576687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 10 mg
Number of subjects: 285
Study 25576687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 14 mg
Number of subjects: 285
Study 25576687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 24142299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with standard meal (540 kcal, 21 g fat)
Number of subjects: 24
Study 24142299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with light meal (390 kcal, 12 g fat)
Number of subjects: 24
Study 24142299 — intervention group
Group type: COMPARATOR
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) under fasted conditions
Number of subjects: 24
Study 22434737 — intervention group
Group type: EXPERIMENTAL
Intervention: GROWTH MONITORING
Number of subjects: 182
Study 22434737 — intervention group
Group type: EXPERIMENTAL
Intervention: DECREASE (GROWTH MONITORING + reducing snack foods and sugar-sweetened beverages)
Number of subjects: 182
Study 22434737 — intervention group
Group type: EXPERIMENTAL
Intervention: INCREASE (GROWTH MONITORING + increasing fruits, vegetables and low-fat dairy)
Number of subjects: 182
Study 22434737 — intervention group
Group type: EXPERIMENTAL
Intervention: TRADITIONAL (GROWTH MONITORING + decreasing sugar-sweetened beverages and increasing physical activity)
Number of subjects: 182
Study 22434737 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBSTITUTES (GROWTH MONITORING + increasing low-fat milk consumption and reducing television watching)
Number of subjects: 182
Study 19382202 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tretinoin Chemoprevention
Number of subjects: 169
Study 17697552 — intervention group
Group type: EXPERIMENTAL
Intervention: TP regimen (docetaxel combined with cisplatin)
Number of subjects: 40
Study 17697552 — intervention group
Group type: COMPARATOR
Intervention: PF regimen (cisplatin combined with 5-fluorouracil)
Number of subjects: 40
Study 15522370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injection (0.1 ml)
Number of subjects: 43
Study 15522370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injection
Number of subjects: 43
Study 15522370 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (subconjunctival saline)
Number of subjects: 43
Study 11851051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage A
Number of subjects: 0
Study 11851051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage B
Number of subjects: 0
Study 11851051 — intervention group
Group type: COMPARATOR
Intervention: Bandage A and B
Number of subjects: 0
Study 9248828 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment program (12 weeks)
Number of subjects: 100
Study 9248828 — intervention group
Group type: EXPERIMENTAL
Intervention: Camberwell Family Interview (CFI) variables: Critical Comments, Emotional Overinvolvement, Warmth
Number of subjects: 100
Study 9248828 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Overinvolvement of significant other
Number of subjects: 100
Study 9248828 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Comments made by relatives
Number of subjects: 100
Study 7936850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention with biweekly nurse visits beginning before delivery and extending through 18 months of life.
Number of subjects: 60
Study 7936850 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 60
Study 2901839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (less than or equal to 3 gm/day, mean 2.5)
Number of subjects: 85
Study 2901839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 28689678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint-Interval Exercise (SIE)
Number of subjects: 8
Study 28689678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8
Study 28689678 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMIE)
Number of subjects: 8
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate-emtricitabine
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use only
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP and condom use
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom-use only
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: No PrEP or condom use
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled PrEP use
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless receptive anal intercourse
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP intake or condom use or both
Number of subjects: 400
Study 26883400 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of sexual partners
Number of subjects: 400
Study 25596004 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention (diet modification, regular exercise, psychosocial consultation)
Number of subjects: 41